biotech / news / / The Manila Times
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone.
Pluvicto combined with standard therapy reduces risk of PSA progression by 58% versus standard care alone.
KEY POINTS
- At 48 weeks, 87.4% of Pluvicto-treated patients achieved deep PSA reduction, vs 74.9% with standard care.
- Grade ≥3 adverse events occurred in 50.7% of Pluvicto combination patients, slightly higher than 43% on standard therapy.
- Regulatory submissions for Pluvicto in mHSPC have been filed in the US, China, and Japan, with decisions expected H2 2026.
- Pluvicto is the first radioligand therapy to show clinical benefit for PSMA+ mHSPC in a Phase III trial.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →